All In Biotech

Drug Trial Radar · NCT01435759

SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

A Phase 2, Multicenter, Double- Blind, Parallel-group, Randomized, Placebo-controlled, Forced-dose Titration, Dose-ranging Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant

Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,197 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,197

Actual

Start

May 31, 2011

Primary completion

Jan 17, 2014

Study completion Jan 17, 2014

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms. The purpose of this study is to help answer the following questions: * How safe is SPD489 for the supplemental treatment of depression and what are the side effects that might be related to it? * Can SPD489 help patients with depression who are also taking an antidepressant? * How much SPD489 should be given to patients with depression who are also taking an antidepressant? * How does SPD489 compare to placebo in depressed patients who are also taking an antidepressant?

Conditions

  • Major Depressive Disorder

Interventions

  • Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mgDrug

    Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks

  • Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mgDrug

    Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks

  • Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mgDrug

    Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks

  • Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mgDrug

    Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks

  • Antidepressant + PlaceboDrug

    oral, once daily for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)Time frame: Augmentation Baseline (Week 8) to Week 16

Locations

82 sites in 5 countries. Site status is shown where the registry gives one.

  • Arkansas Psychiatric Clinic Clinical Research Trials

    Little Rock, Arkansas

  • South Coast Clinical Trials

    Anaheim, California

  • Catalina Research Institute, LLC

    Chino, California

  • Shanti Clinical Trials

    Colton, California

  • Clinical Innovation, Inc.

    Costa Mesa, California

  • Collaborative Neuroscience Network, Inc.

    Garden Grove, California

  • Irvine Center for Clinical Research

    Irvine, California

  • Omega Clinical Trials

    La Habra, California

  • Provate Practice of Andrew Leuchter, MD

    Los Angeles, California

  • PCSD - Feighner Research

    San Diego, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • Neuropsychiatric Research Center of Orange County

    Santa Ana, California

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California

  • Western Affiliated Research Institute

    Denver, Colorado

  • Connecticut Clinical Research

    Cromwell, Connecticut

  • Institute of Living

    Hartford, Connecticut

  • The Hospital of Central Connecticut, Psychiatry & Behavioral Health Research

    New Britain, Connecticut

  • Gulfcoast Clinical Research Center

    Fort Myers, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Clinical Neuroscience Solutions, Inc.

    Jacksonville, Florida

  • Private Practice - Amit Vijapura MD

    Jacksonville, Florida

  • Psychiatric Associates

    Lake City, Florida

  • Comprehensive Neuroscience, Inc.

    Miramar, Florida

  • Fideltiy Clinical Research, Inc.

    North Miami, Florida

  • Ali A. Kashfi, MD, PA

    Orlando, Florida

  • Clinical Research of Central Florida

    Winter Haven, Florida

  • Kolin Research Group

    Winter Park, Florida

  • Institute for Behavioral Medicine, LLC

    Smyrna, Georgia

  • Treatment Research Center, Rush University Medical Center

    Chicago, Illinois

  • Alexian Brothers Center for Psychiatric Research

    Hoffman Estates, Illinois

  • Psychiatric Medicine Associates, LLC

    Skokie, Illinois

  • Sleep and Behavior Medicine Institute

    Vernon Hills, Illinois

  • Clinical Trials Technology, Inc.

    Prairie Village, Kansas

  • Pedia Research, LLC

    Owensboro, Kentucky

  • Psyichatric Care and Research Center

    O'Fallon, Missouri

  • Mid-America Clinical Research, LLC

    St Louis, Missouri

  • Premier Psychiatric Research Institute, LLC.

    Lincoln, Nebraska

  • Clinical Research Consortium

    Las Vegas, Nevada

  • Center for Emotional Fitness

    Cherry Hill, New Jersey

  • CRI Worldwide LLC

    Willingboro, New Jersey

Showing 40 of 82 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.